Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Williams

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
JBMR Plus|October 1, 2025
Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH RegistryAgnès Linglart, Cyril Amouroux, Iva Gueorguieva, et al.
Plos One|January 19, 2024
A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)Vrinda Saraff, Annemieke M Boot, Agnès Linglart, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2002
Spirocyclic NK(1) antagonists II: [4.5]-spiroethersBrian J Williams, Margaret A Cascieri, Gary G Chicchi, et al.
Plos One|June 11, 2013
A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivoJonathan S Wall, Angela Williams, Tina Richey, et al.
Plos One|March 29, 2017
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensityEmily B Martin, Angela Williams, Craig Wooliver, et al.
Molecules (Basel, Switzerland)|April 30, 2015
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral AmyloidosisJonathan S Wall, Emily B Martin, Tina Richey, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 14, 2023
Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods AnalysisSuzanne M Jan de Beur, Tricia Cimms, Annabel Nixon, et al.
Journal of Interpersonal Violence|December 29, 2020
The Readiness of Australian Health Care Students to Encounter Patients Experiencing Partner AbuseSimon Sawyer, Michal Schneider, Deborah Western, et al.
The Journal of Infectious Diseases|October 11, 2015
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older AdultsMyron J Levin, Kenneth E Schmader, Lei Pang, et al.
Leukemia|December 5, 2019
Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cellsTorri L Jordan, Khansaa Maar, Keely R Redhage, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
JBMR Plus|October 1, 2025
Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH RegistryAgnès Linglart, Cyril Amouroux, Iva Gueorguieva, et al.
Plos One|January 19, 2024
A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)Vrinda Saraff, Annemieke M Boot, Agnès Linglart, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2002
Spirocyclic NK(1) antagonists II: [4.5]-spiroethersBrian J Williams, Margaret A Cascieri, Gary G Chicchi, et al.
Plos One|June 11, 2013
A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivoJonathan S Wall, Angela Williams, Tina Richey, et al.
Plos One|March 29, 2017
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensityEmily B Martin, Angela Williams, Craig Wooliver, et al.
Molecules (Basel, Switzerland)|April 30, 2015
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral AmyloidosisJonathan S Wall, Emily B Martin, Tina Richey, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 14, 2023
Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods AnalysisSuzanne M Jan de Beur, Tricia Cimms, Annabel Nixon, et al.
Journal of Interpersonal Violence|December 29, 2020
The Readiness of Australian Health Care Students to Encounter Patients Experiencing Partner AbuseSimon Sawyer, Michal Schneider, Deborah Western, et al.
The Journal of Infectious Diseases|October 11, 2015
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older AdultsMyron J Levin, Kenneth E Schmader, Lei Pang, et al.
Leukemia|December 5, 2019
Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cellsTorri L Jordan, Khansaa Maar, Keely R Redhage, et al.
Pageof 14